epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
Avasopasem
avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Qivigy (immune globulin human-kthm)

immune globulin (human)

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Black Box Warnings .

Thrombosis

may occur with immune globulin products; risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, venous or arterial thrombosis history, estrogen use, indwelling central vascular catheter, hyperviscosity, and cardiovascular disease risk; thrombosis may occur in patients without risk factors; ensure adequate hydration before administration; give minimum dose at lowest infusion rate practicable in patients at risk; monitor for signs/symptoms of thrombosis and assess blood viscosity in patients with hyperviscosity risk

Renal Dysfunction/Acute Renal Failure

renal dysfunction, acute renal failure, osmotic nephrosis, and death reported with intravenous immune globulin (IVIG) use; patients predisposed to acute renal failure including those with pre-existing renal impairment, diabetes mellitus, volume depletion, sepsis, paraproteinemia, >65 yo, or receiving nephrotoxic drugs; ensure adequate hydration before administration; administer IVIG at minimum dose and lowest infusion rate practicable in patients at risk; IVIG products containing sucrose as stabilizer accounted for disproportionate share of renal dysfunction/failure cases; this product does not contain sucrose

Adult Dosing .

Dosage forms:  INJ

Special Note

[drug name clarification]
Info: nonproprietary name = immune globulin human-kthm
[uses, dosing may vary]
Info: refer to institution protocols and pkg insert prior to prescribing

primary immunodeficiency

[300-800 mg/kg/dose IV q3-4wk]
Info: adjust dose based on trough IgG levels and clinical response; give 400 mg/kg/dose IV x1 ASAP if measles exposure; if maintenance dose <400 mg/kg/dose IV q3-4wk and measles exposure risk, give 400 mg/kg/dose IV x1 just prior to exposure

idiopathic thrombocytopenic purpura (off-label)

[1000 mg/kg/dose IV x1 on day 1, may give additional dose x1 on subsequent day]
Alt: 400 mg/kg/dose IV qd x5 days; Info: may repeat q3-4wk prn

secondary immunodeficiency, B-CLL associated (off-label)

[400 mg/kg/dose IV q3-4wk]

chronic inflammatory demyelinating polyneuropathy (off-label)

[1000 mg/kg/dose IV q3wk]
Start: 2000 mg/kg/total dose IV divided over 2-5 days, infused daily; Alt: 500 mg/kg/dose IV qd x2 days, given q3wk

myasthenia gravis (off-label)

[400 mg/kg/dose IV qd x5 days]
Max: 1000 mg/kg/day; Alt: 1000 mg/kg/dose IV qd x2 days

renal dosing

[see below]
renal impairment: not defined, caution advised; Info: use minimum dose and infusion rate practicable
HD/PD: not defined

hepatic dosing

[not defined]

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@3e88c937
  • hypersensitivity to drug or ingredient
  • caution: IgA deficiency
  • caution: nephrotoxic agent use, concurrent
  • caution: patients >65 yo
  • caution: renal impairment
  • caution: renal impairment risk
  • caution: paraproteinemia
  • caution: migraine history
  • caution: thrombosis risk
  • caution: hyperviscosity
  • caution: A blood group
  • caution: AB blood group
  • caution: B blood group
  • caution: inflammatory disorder
  • caution: high-dose use
  • caution: volume overload (immune thrombocytopenia use)

Drug Interactions .

Overview

immune globulin

immunoglobulin

Interaction Characteristics:
  • immunomodulatory effects (immune globulin)
  • nephrotoxicity
  • thrombogenic effects
Other Info
  • monitor renal function; nephrotoxicity risk may be higher with sucrose-containing immune globulins, may vary depending on route of administration

Contraindicated

  • cidofovir
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    cidofovir
    1 interaction

    Contraindicated

    immune globulin + cidofovir

    contraindicated; D/C immune globulin at least 7 days prior to cidofovir tx: combo may incr. cidofovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

Avoid/Use Alternative

  • aldesleukin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    aldesleukin
    1 interaction

    Avoid/Use Alternative

    immune globulin + aldesleukin

    use alternative or monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • amikacin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    amikacin
    1 interaction

    Avoid/Use Alternative

    immune globulin + amikacin

    use alternative or monitor amikacin levels, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • amikacin inhaled
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    amikacin inhaled
    1 interaction

    Avoid/Use Alternative

    immune globulin + amikacin inhaled

    use alternative or monitor renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. amikacin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • bumetanide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    bumetanide
    1 interaction

    Avoid/Use Alternative

    immune globulin + bumetanide

    use alternative or monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • clofarabine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    clofarabine
    1 interaction

    Avoid/Use Alternative

    immune globulin + clofarabine

    avoid immune globulin during 5 day clofarabine tx; monitor CBC, renal fxn, BP; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. clofarabine levels, risk of serious infection, myelosuppression, nephrotoxicity, hypotension, other adverse effects (additive effects)

  • efgartigimod alfa
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    efgartigimod alfa
    1 interaction

    Avoid/Use Alternative

    immune globulin + efgartigimod alfa

    consider alternative if long-term use: combo may decr. immune globulin levels, efficacy (FcRn blockade)

  • ethacrynic acid
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ethacrynic acid
    1 interaction

    Avoid/Use Alternative

    immune globulin + ethacrynic acid

    use alternative or monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • foscarnet
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    foscarnet
    1 interaction

    Avoid/Use Alternative

    immune globulin + foscarnet

    use alternative or monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. foscarnet levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • furosemide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    furosemide
    1 interaction

    Avoid/Use Alternative

    immune globulin + furosemide

    use alternative or monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • ganciclovir
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ganciclovir
    1 interaction

    Avoid/Use Alternative

    immune globulin + ganciclovir

    use alternative or monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • gentamicin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    gentamicin
    1 interaction

    Avoid/Use Alternative

    immune globulin + gentamicin

    use alternative or monitor gentamicin levels, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. gentamicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • immune globulin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    immune globulin
    1 interaction

    Avoid/Use Alternative

    immune globulin + immune globulin

    avoid combo: combo may incr. risk of nephrotoxicity, thromboembolism, other adverse effects (additive effects, duplicate therapy)

  • mannitol
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    mannitol
    1 interaction

    Avoid/Use Alternative

    immune globulin + mannitol

    use alternative or monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. mannitol levels, risk of nephrotoxicity, neurotoxicity (including life-threatening), other adverse effects (additive effects)

  • methotrexate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    methotrexate
    1 interaction

    Avoid/Use Alternative

    immune globulin + methotrexate

    use alternative or monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • nipocalimab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    nipocalimab
    1 interaction

    Avoid/Use Alternative

    immune globulin + nipocalimab

    consider alternative if long-term use: combo may decr. immune globulin levels, efficacy (FcRn blockade)

  • oxaliplatin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    oxaliplatin
    1 interaction

    Avoid/Use Alternative

    immune globulin + oxaliplatin

    use alternative or monitor ECG, CBC, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. oxaliplatin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • pentamidine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    pentamidine
    1 interaction

    Avoid/Use Alternative

    immune globulin + pentamidine

    use alternative or monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • polymyxin B
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    polymyxin B
    1 interaction

    Avoid/Use Alternative

    immune globulin + polymyxin B

    avoid combo: combo may incr. risk of nephrotoxicity (additive effects)

  • pozelimab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    pozelimab
    1 interaction

    Avoid/Use Alternative

    immune globulin + pozelimab

    use alternative: combo may decr. pozelimab levels, efficacy (FcRn blockade)

  • rozanolixizumab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    rozanolixizumab
    1 interaction

    Avoid/Use Alternative

    immune globulin + rozanolixizumab

    consider alternative if long-term use: combo may decr. immune globulin levels, efficacy (FcRn blockade)

  • streptomycin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    streptomycin
    1 interaction

    Avoid/Use Alternative

    immune globulin + streptomycin

    use alternative or monitor renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. streptomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • streptozocin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    streptozocin
    1 interaction

    Avoid/Use Alternative

    immune globulin + streptozocin

    use alternative or monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • tenofovir disoproxil
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tenofovir disoproxil
    1 interaction

    Avoid/Use Alternative

    immune globulin + tenofovir disoproxil

    use alternative or monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • tobramycin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tobramycin
    1 interaction

    Avoid/Use Alternative

    immune globulin + tobramycin

    use alternative or monitor tobramycin levels, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • tobramycin inhaled
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tobramycin inhaled
    1 interaction

    Avoid/Use Alternative

    immune globulin + tobramycin inhaled

    use alternative or monitor renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. tobramycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • torsemide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    torsemide
    1 interaction

    Avoid/Use Alternative

    immune globulin + torsemide

    use alternative or monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • tranexamic acid
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tranexamic acid
    1 interaction

    Avoid/Use Alternative

    immune globulin + tranexamic acid

    avoid combo: combo may incr. risk of thromboembolism (additive effects)

  • vaccinia immune globulin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    vaccinia immune globulin
    1 interaction

    Avoid/Use Alternative

    immune globulin + vaccinia immune globulin

    use alternative or monitor thrombosis s/sx, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism, nephrotoxicity (additive effects)

  • valganciclovir
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    valganciclovir
    1 interaction

    Avoid/Use Alternative

    immune globulin + valganciclovir

    use alternative or monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. ganciclovir levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

Monitor/Modify Tx

  • abemaciclib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    abemaciclib
    1 interaction

    Monitor/Modify Tx

    immune globulin + abemaciclib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • abrocitinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    abrocitinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + abrocitinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • acyclovir
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    acyclovir
    1 interaction

    Monitor/Modify Tx

    immune globulin + acyclovir

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • adefovir dipivoxil
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    adefovir dipivoxil
    1 interaction

    Monitor/Modify Tx

    immune globulin + adefovir dipivoxil

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. adefovir levels, risk of nephrotoxicity, other adverse effects (renal excretion decreased by nephrotoxic agents, additive effects)

  • adenovirus vaccine, live
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    adenovirus vaccine, live
    1 interaction

    Monitor/Modify Tx

    immune globulin + adenovirus vaccine, live

    consider vaccinating at least 2wk before or 8-11mo after IVIG tx; if vaccine given shortly before IVIG, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

  • aflibercept
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    aflibercept
    1 interaction

    Monitor/Modify Tx

    immune globulin + aflibercept

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • alectinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    alectinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + alectinib

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • aliskiren
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    aliskiren
    1 interaction

    Monitor/Modify Tx

    immune globulin + aliskiren

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • allopurinol
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    allopurinol
    1 interaction

    Monitor/Modify Tx

    immune globulin + allopurinol

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • amiloride
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    amiloride
    1 interaction

    Monitor/Modify Tx

    immune globulin + amiloride

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • aminocaproic acid
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    aminocaproic acid
    1 interaction

    Monitor/Modify Tx

    immune globulin + aminocaproic acid

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • amphotericin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    amphotericin
    1 interaction

    Monitor/Modify Tx

    immune globulin + amphotericin

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • angiotensin II
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    angiotensin II
    1 interaction

    Monitor/Modify Tx

    immune globulin + angiotensin II

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • anthrax immune globulin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    anthrax immune globulin
    1 interaction

    Monitor/Modify Tx

    immune globulin + anthrax immune globulin

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration, and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • anti-inhibitor coagulant complex
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    anti-inhibitor coagulant complex
    1 interaction

    Monitor/Modify Tx

    immune globulin + anti-inhibitor coagulant complex

    monitor thrombosis s/sx, especially w/ anti-inhibitor coagulant complex dose >100 units/kg; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • antihemophilic factor (factor VIII)/von Willebrand factor complex
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    antihemophilic factor (factor VIII)/ von Willebrand factor complex
    1 interaction

    Monitor/Modify Tx

    immune globulin + antihemophilic factor (factor VIII)/ von Willebrand factor complex

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • asciminib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    immune globulin + asciminib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • asparaginase
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    asparaginase
    1 interaction

    Monitor/Modify Tx

    immune globulin + asparaginase

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • aspirin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    aspirin
    1 interaction

    Monitor/Modify Tx

    immune globulin + aspirin

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • atidarsagene autotemcel
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    atidarsagene autotemcel
    1 interaction

    Monitor/Modify Tx

    immune globulin + atidarsagene autotemcel

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • auranofin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    auranofin
    1 interaction

    Monitor/Modify Tx

    immune globulin + auranofin

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. auranofin levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • avatrombopag
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    avatrombopag
    1 interaction

    Monitor/Modify Tx

    immune globulin + avatrombopag

    monitor platelets, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • axitinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + axitinib

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • azilsartan medoxomil
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    azilsartan medoxomil
    1 interaction

    Monitor/Modify Tx

    immune globulin + azilsartan medoxomil

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • balsalazide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    balsalazide
    1 interaction

    Monitor/Modify Tx

    immune globulin + balsalazide

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • baricitinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    baricitinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + baricitinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • bazedoxifene
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    bazedoxifene
    1 interaction

    Monitor/Modify Tx

    immune globulin + bazedoxifene

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • benazepril
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    benazepril
    1 interaction

    Monitor/Modify Tx

    immune globulin + benazepril

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • bevacizumab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    immune globulin + bevacizumab

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • binimetinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    binimetinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + binimetinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • bleomycin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    bleomycin
    1 interaction

    Monitor/Modify Tx

    immune globulin + bleomycin

    monitor renal fxn; decr. bleomycin dose based on CrCl: combo may incr. bleomycin levels, risk of pulmonary toxicities (including life-threatening), other adverse effects (renal excretion decreased)

  • botulism immune globulin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    botulism immune globulin
    1 interaction

    Monitor/Modify Tx

    immune globulin + botulism immune globulin

    monitor renal fxn, thrombosis s/sx; use lowest effective dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • brolucizumab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    brolucizumab
    1 interaction

    Monitor/Modify Tx

    immune globulin + brolucizumab

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • C1 esterase inhibitor
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    C1 esterase inhibitor
    1 interaction

    Monitor/Modify Tx

    immune globulin + C1 esterase inhibitor

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • cabozantinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + cabozantinib

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • calaspargase
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    calaspargase
    1 interaction

    Monitor/Modify Tx

    immune globulin + calaspargase

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • candesartan cilexetil
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    candesartan cilexetil
    1 interaction

    Monitor/Modify Tx

    immune globulin + candesartan cilexetil

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • capecitabine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    capecitabine
    1 interaction

    Monitor/Modify Tx

    immune globulin + capecitabine

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • captopril
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    captopril
    1 interaction

    Monitor/Modify Tx

    immune globulin + captopril

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • carboplatin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    carboplatin
    1 interaction

    Monitor/Modify Tx

    immune globulin + carboplatin

    monitor CBC, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. carboplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • carfilzomib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    carfilzomib
    1 interaction

    Monitor/Modify Tx

    immune globulin + carfilzomib

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • celecoxib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    immune globulin + celecoxib

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective celecoxib dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • chlorothiazide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    immune globulin + chlorothiazide

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • chlorthalidone
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    immune globulin + chlorthalidone

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • chorionic gonadotropin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    chorionic gonadotropin
    1 interaction

    Monitor/Modify Tx

    immune globulin + chorionic gonadotropin

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • cisplatin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    cisplatin
    1 interaction

    Monitor/Modify Tx

    immune globulin + cisplatin

    monitor CBC, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. cisplatin levels, risk of serious infection, myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • clindamycin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    clindamycin
    1 interaction

    Monitor/Modify Tx

    immune globulin + clindamycin

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • clozapine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    immune globulin + clozapine

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • coagulation factor IX
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    coagulation factor IX
    1 interaction

    Monitor/Modify Tx

    immune globulin + coagulation factor IX

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • coagulation factor VIIa
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    coagulation factor VIIa
    1 interaction

    Monitor/Modify Tx

    immune globulin + coagulation factor VIIa

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • coagulation factor XIII A-subunit
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    coagulation factor XIII A-subunit
    1 interaction

    Monitor/Modify Tx

    immune globulin + coagulation factor XIII A-subunit

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • colistimethate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    colistimethate
    1 interaction

    Monitor/Modify Tx

    immune globulin + colistimethate

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. colistimethate levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • concizumab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    concizumab
    1 interaction

    Monitor/Modify Tx

    immune globulin + concizumab

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • copper histidinate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    copper histidinate
    1 interaction

    Monitor/Modify Tx

    immune globulin + copper histidinate

    monitor renal fxn, electrolytes; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • creatine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    creatine
    1 interaction

    Monitor/Modify Tx

    immune globulin + creatine

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • cyclophosphamide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    immune globulin + cyclophosphamide

    monitor CBC, renal, cardiac fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. cyclophosphamide levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)

  • cyclosporine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    immune globulin + cyclosporine

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • cytomegalovirus immune globulin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    cytomegalovirus immune globulin
    1 interaction

    Monitor/Modify Tx

    immune globulin + cytomegalovirus immune globulin

    monitor renal fxn, thrombosis s/sx; use lowest effective dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • danazol
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    immune globulin + danazol

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • darbepoetin alfa
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    darbepoetin alfa
    1 interaction

    Monitor/Modify Tx

    immune globulin + darbepoetin alfa

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • deferasirox
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    deferasirox
    1 interaction

    Monitor/Modify Tx

    immune globulin + deferasirox

    monitor CBC, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. deferasirox levels, risk of myelosuppression, nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • deferoxamine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    deferoxamine
    1 interaction

    Monitor/Modify Tx

    immune globulin + deferoxamine

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • deflazacort
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    deflazacort
    1 interaction

    Monitor/Modify Tx

    immune globulin + deflazacort

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • dengue vaccine, live
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    dengue vaccine, live
    1 interaction

    Monitor/Modify Tx

    immune globulin + dengue vaccine, live

    consider vaccinating at least 2wk before or 8-11mo after IVIG tx; if vaccine given shortly before IVIG, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

  • desogestrel (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    desogestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + desogestrel (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • deuruxolitinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    deuruxolitinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + deuruxolitinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • dexamethasone
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    dexamethasone
    1 interaction

    Monitor/Modify Tx

    immune globulin + dexamethasone

    monitor thrombosis s/sx, especially if multiple myeloma use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • diclofenac
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    immune globulin + diclofenac

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • diclofenac topical
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    diclofenac topical
    1 interaction

    Monitor/Modify Tx

    immune globulin + diclofenac topical

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • dienogest (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    dienogest (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + dienogest (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • diflunisal
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    diflunisal
    1 interaction

    Monitor/Modify Tx

    immune globulin + diflunisal

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective diflunisal dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • drospirenone (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    drospirenone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + drospirenone (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • drospirenone (hormone replacement)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    drospirenone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    immune globulin + drospirenone (hormone replacement)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • eculizumab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    eculizumab
    1 interaction

    Monitor/Modify Tx

    immune globulin + eculizumab

    MYASTHENIA GRAVIS: adjust eculizumab dose as follows per IVIG cycle: acute rescue: no supplement; IVIG q4wk or more often: give additional 600 mg (most recent eculizumab dose 900 mg or more) or 300 mg (most recent dose 600 mg or less) with scheduled eculizumab doses; IVIG given less often than q4wk: give additional 600 mg (most recent eculizumab dose 900 mg or more) or 300 mg (most recent dose 600 mg or less) with next scheduled eculizumab dose after last IVIG cycle; OTHER USES: caution advised: combo may decr. eculizumab levels, efficacy (possible FcRn blockade)

  • eltrombopag
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    eltrombopag
    1 interaction

    Monitor/Modify Tx

    immune globulin + eltrombopag

    monitor platelets, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • enalapril
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    enalapril
    1 interaction

    Monitor/Modify Tx

    immune globulin + enalapril

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • enalaprilat
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    enalaprilat
    1 interaction

    Monitor/Modify Tx

    immune globulin + enalaprilat

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • epirubicin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    epirubicin
    1 interaction

    Monitor/Modify Tx

    immune globulin + epirubicin

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • epoetin alfa
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    epoetin alfa
    1 interaction

    Monitor/Modify Tx

    immune globulin + epoetin alfa

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • estetrol (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    estetrol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + estetrol (contraceptive)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • estradiol (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + estradiol (contraceptive)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • estradiol (hormone replacement)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    estradiol (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    immune globulin + estradiol (hormone replacement)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • estrogens, conjugated (hormone replacement)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    estrogens, conjugated (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    immune globulin + estrogens, conjugated (hormone replacement)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • estrogens, esterified (hormone replacement)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    estrogens, esterified (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    immune globulin + estrogens, esterified (hormone replacement)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • ethinyl estradiol (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + ethinyl estradiol (contraceptive)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • ethinyl estradiol (hormone replacement)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ethinyl estradiol (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    immune globulin + ethinyl estradiol (hormone replacement)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • ethynodiol (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ethynodiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + ethynodiol (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • etodolac
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    etodolac
    1 interaction

    Monitor/Modify Tx

    immune globulin + etodolac

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective etodolac dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • etonogestrel (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    etonogestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + etonogestrel (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • everolimus
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    immune globulin + everolimus

    monitor renal fxn, thrombosis s/sx especially if immunosuppressant use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • factor XIII concentrate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    factor XIII concentrate
    1 interaction

    Monitor/Modify Tx

    immune globulin + factor XIII concentrate

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • faricimab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    faricimab
    1 interaction

    Monitor/Modify Tx

    immune globulin + faricimab

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • fedratinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    fedratinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + fedratinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • fenofibrate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    fenofibrate
    1 interaction

    Monitor/Modify Tx

    immune globulin + fenofibrate

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • fenofibric acid
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    fenofibric acid
    1 interaction

    Monitor/Modify Tx

    immune globulin + fenofibric acid

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • fenoprofen
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    fenoprofen
    1 interaction

    Monitor/Modify Tx

    immune globulin + fenoprofen

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective fenoprofen dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • fibrinogen (human)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    fibrinogen (human)
    1 interaction

    Monitor/Modify Tx

    immune globulin + fibrinogen (human)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • fitusiran
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    fitusiran
    1 interaction

    Monitor/Modify Tx

    immune globulin + fitusiran

    monitor antithrombin activity level, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • flucytosine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    flucytosine
    1 interaction

    Monitor/Modify Tx

    immune globulin + flucytosine

    monitor CBC, renal fxn, flucytosine levels; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. flucytosine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • flurbiprofen
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    flurbiprofen
    1 interaction

    Monitor/Modify Tx

    immune globulin + flurbiprofen

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective flurbiprofen dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • follitropin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    follitropin
    1 interaction

    Monitor/Modify Tx

    immune globulin + follitropin

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • fosinopril
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    fosinopril
    1 interaction

    Monitor/Modify Tx

    immune globulin + fosinopril

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • fruquintinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    fruquintinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + fruquintinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • hepatitis B immune globulin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    hepatitis B immune globulin
    1 interaction

    Monitor/Modify Tx

    immune globulin + hepatitis B immune globulin

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • hydrochlorothiazide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    immune globulin + hydrochlorothiazide

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • hydroxocobalamin IV
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    hydroxocobalamin IV
    1 interaction

    Monitor/Modify Tx

    immune globulin + hydroxocobalamin IV

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • ibuprofen
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ibuprofen
    1 interaction

    Monitor/Modify Tx

    immune globulin + ibuprofen

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective ibuprofen dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • ibuprofen lysine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ibuprofen lysine
    1 interaction

    Monitor/Modify Tx

    immune globulin + ibuprofen lysine

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • ifosfamide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ifosfamide
    1 interaction

    Monitor/Modify Tx

    immune globulin + ifosfamide

    monitor CBC, renal, cardiac fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. ifosfamide levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (additive effects)

  • indapamide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    immune globulin + indapamide

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • indomethacin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    indomethacin
    1 interaction

    Monitor/Modify Tx

    immune globulin + indomethacin

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective indomethacin dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • iodixanol
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    iodixanol
    1 interaction

    Monitor/Modify Tx

    immune globulin + iodixanol

    monitor renal function, thrombosis signs/symptoms; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • iohexol
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    iohexol
    1 interaction

    Monitor/Modify Tx

    immune globulin + iohexol

    monitor renal fxn, thrombosis s/sx if IV iohexol use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • iomeprol
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    iomeprol
    1 interaction

    Monitor/Modify Tx

    immune globulin + iomeprol

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • iopamidol
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    iopamidol
    1 interaction

    Monitor/Modify Tx

    immune globulin + iopamidol

    if IV iopamidol use, monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • iopromide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    iopromide
    1 interaction

    Monitor/Modify Tx

    immune globulin + iopromide

    monitor renal function, thrombosis signs/symptoms; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • iothalamate meglumine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    iothalamate meglumine
    1 interaction

    Monitor/Modify Tx

    immune globulin + iothalamate meglumine

    if IV iothalamate meglumine use, monitor renal function, thrombosis signs/symptoms; use lowest immune globulin dose, concentration and infusion rate possible; retrograde cystography and cystourethrography use OK: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • ioversol
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ioversol
    1 interaction

    Monitor/Modify Tx

    immune globulin + ioversol

    monitor renal function, thrombosis signs/symptoms; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • irbesartan
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    irbesartan
    1 interaction

    Monitor/Modify Tx

    immune globulin + irbesartan

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • ketoprofen
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ketoprofen
    1 interaction

    Monitor/Modify Tx

    immune globulin + ketoprofen

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective ketoprofen dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • ketorolac
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ketorolac
    1 interaction

    Monitor/Modify Tx

    immune globulin + ketorolac

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective ketorolac dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • lazertinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    lazertinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + lazertinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • lenalidomide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    lenalidomide
    1 interaction

    Monitor/Modify Tx

    immune globulin + lenalidomide

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • lenvatinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + lenvatinib

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • levonorgestrel (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    levonorgestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + levonorgestrel (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • levonorgestrel (hormone replacement)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    levonorgestrel (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    immune globulin + levonorgestrel (hormone replacement)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • lifileucel
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    lifileucel
    1 interaction

    Monitor/Modify Tx

    immune globulin + lifileucel

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • lisinopril
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    lisinopril
    1 interaction

    Monitor/Modify Tx

    immune globulin + lisinopril

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • lithium
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    lithium
    1 interaction

    Monitor/Modify Tx

    immune globulin + lithium

    monitor lithium levels, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. lithium levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • lomustine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    lomustine
    1 interaction

    Monitor/Modify Tx

    immune globulin + lomustine

    monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. lomustine levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • losartan
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    losartan
    1 interaction

    Monitor/Modify Tx

    immune globulin + losartan

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • luspatercept
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    luspatercept
    1 interaction

    Monitor/Modify Tx

    immune globulin + luspatercept

    if beta thalassemia use, monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • lusutrombopag
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    lusutrombopag
    1 interaction

    Monitor/Modify Tx

    immune globulin + lusutrombopag

    monitor platelets, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • lutetium Lu 177 vipivotide tetraxetan
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    lutetium Lu 177 vipivotide tetraxetan
    1 interaction

    Monitor/Modify Tx

    immune globulin + lutetium Lu 177 vipivotide tetraxetan

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • magnesium citrate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    magnesium citrate
    1 interaction

    Monitor/Modify Tx

    immune globulin + magnesium citrate

    monitor renal fxn, especially if magnesium citrate bowel prep use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • magnesium salicylate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    immune globulin + magnesium salicylate

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • measles/mumps/rubella vaccine, live
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    measles/ mumps/ rubella vaccine, live
    1 interaction

    Monitor/Modify Tx

    immune globulin + measles/ mumps/ rubella vaccine, live

    vaccinate at least 2wk before or 8-11mo after IVIG tx; if vaccine given shortly before IVIG, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

  • meclofenamate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    meclofenamate
    1 interaction

    Monitor/Modify Tx

    immune globulin + meclofenamate

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective meclofenamate dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • medroxyprogesterone (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    medroxyprogesterone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + medroxyprogesterone (contraceptive)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • medroxyprogesterone (hormone replacement)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    medroxyprogesterone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    immune globulin + medroxyprogesterone (hormone replacement)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • mefenamic acid
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    mefenamic acid
    1 interaction

    Monitor/Modify Tx

    immune globulin + mefenamic acid

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective mefenamic acid dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • megestrol
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    megestrol
    1 interaction

    Monitor/Modify Tx

    immune globulin + megestrol

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • meloxicam
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    meloxicam
    1 interaction

    Monitor/Modify Tx

    immune globulin + meloxicam

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective meloxicam dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • menotropins
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    menotropins
    1 interaction

    Monitor/Modify Tx

    immune globulin + menotropins

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • mesalamine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    mesalamine
    1 interaction

    Monitor/Modify Tx

    immune globulin + mesalamine

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • mesalamine rectal
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    mesalamine rectal
    1 interaction

    Monitor/Modify Tx

    immune globulin + mesalamine rectal

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • methoxy polyethylene glycol-epoetin beta
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    methoxy polyethylene glycol-epoetin beta
    1 interaction

    Monitor/Modify Tx

    immune globulin + methoxy polyethylene glycol-epoetin beta

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • methyltestosterone
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    methyltestosterone
    1 interaction

    Monitor/Modify Tx

    immune globulin + methyltestosterone

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • metolazone
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    immune globulin + metolazone

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • mitomycin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    mitomycin
    1 interaction

    Monitor/Modify Tx

    immune globulin + mitomycin

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of nephrotoxicity (additive effects)

  • moexipril
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    moexipril
    1 interaction

    Monitor/Modify Tx

    immune globulin + moexipril

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • momelotinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    momelotinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + momelotinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • nabumetone
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    nabumetone
    1 interaction

    Monitor/Modify Tx

    immune globulin + nabumetone

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective nabumetone dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • naproxen
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    naproxen
    1 interaction

    Monitor/Modify Tx

    immune globulin + naproxen

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective naproxen dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • necitumumab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    necitumumab
    1 interaction

    Monitor/Modify Tx

    immune globulin + necitumumab

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • neomycin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    neomycin
    1 interaction

    Monitor/Modify Tx

    immune globulin + neomycin

    if compromised gut wall allows for neomycin absorption, monitor renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. neomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • nintedanib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    nintedanib
    1 interaction

    Monitor/Modify Tx

    immune globulin + nintedanib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • norelgestromin (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    norelgestromin (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + norelgestromin (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • norethindrone (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    norethindrone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + norethindrone (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • norethindrone (hormone replacement)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    norethindrone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    immune globulin + norethindrone (hormone replacement)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • norgestimate (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    norgestimate (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + norgestimate (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • norgestrel (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    norgestrel (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + norgestrel (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • nusinersen
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    nusinersen
    1 interaction

    Monitor/Modify Tx

    immune globulin + nusinersen

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • obinutuzumab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    obinutuzumab
    1 interaction

    Monitor/Modify Tx

    immune globulin + obinutuzumab

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • olaparib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    olaparib
    1 interaction

    Monitor/Modify Tx

    immune globulin + olaparib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • olmesartan medoxomil
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    olmesartan medoxomil
    1 interaction

    Monitor/Modify Tx

    immune globulin + olmesartan medoxomil

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • olsalazine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    olsalazine
    1 interaction

    Monitor/Modify Tx

    immune globulin + olsalazine

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • ospemifene
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ospemifene
    1 interaction

    Monitor/Modify Tx

    immune globulin + ospemifene

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • oxaprozin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    oxaprozin
    1 interaction

    Monitor/Modify Tx

    immune globulin + oxaprozin

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective oxaprozin dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • pacritinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    pacritinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + pacritinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • pamidronate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    pamidronate
    1 interaction

    Monitor/Modify Tx

    immune globulin + pamidronate

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. pamidronate levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • paromomycin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    paromomycin
    1 interaction

    Monitor/Modify Tx

    immune globulin + paromomycin

    if compromised gut wall allows for paromomycin absorption, monitor renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. paromomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • pazopanib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    pazopanib
    1 interaction

    Monitor/Modify Tx

    immune globulin + pazopanib

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • pegaspargase
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    pegaspargase
    1 interaction

    Monitor/Modify Tx

    immune globulin + pegaspargase

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • pemetrexed
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    pemetrexed
    1 interaction

    Monitor/Modify Tx

    immune globulin + pemetrexed

    monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. pemetrexed levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • penicillamine
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    penicillamine
    1 interaction

    Monitor/Modify Tx

    immune globulin + penicillamine

    monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. penicillamine levels, risk of myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • pentostatin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    pentostatin
    1 interaction

    Monitor/Modify Tx

    immune globulin + pentostatin

    monitor CBC, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. pentostatin levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (additive effects)

  • perindopril
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    perindopril
    1 interaction

    Monitor/Modify Tx

    immune globulin + perindopril

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • piroxicam
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    piroxicam
    1 interaction

    Monitor/Modify Tx

    immune globulin + piroxicam

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective piroxicam dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • plazomicin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    plazomicin
    1 interaction

    Monitor/Modify Tx

    immune globulin + plazomicin

    monitor plazomicin levels, renal fxn, ototoxicity; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. plazomicin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects)

  • polyethylene glycol
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    polyethylene glycol
    1 interaction

    Monitor/Modify Tx

    immune globulin + polyethylene glycol

    monitor renal fxn, especially if polyethylene glycol bowel prep use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • polyethylene glycol/electrolytes
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Monitor/Modify Tx

    immune globulin + polyethylene glycol/ electrolytes

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • pomalidomide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    pomalidomide
    1 interaction

    Monitor/Modify Tx

    immune globulin + pomalidomide

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • ponatinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ponatinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + ponatinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • porfimer
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    porfimer
    1 interaction

    Monitor/Modify Tx

    immune globulin + porfimer

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • progesterone (hormone replacement)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    progesterone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    immune globulin + progesterone (hormone replacement)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • progesterone vaginal (hormone replacement)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    progesterone vaginal (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    immune globulin + progesterone vaginal (hormone replacement)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • prothrombin complex concentrate (human)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    prothrombin complex concentrate (human)
    1 interaction

    Monitor/Modify Tx

    immune globulin + prothrombin complex concentrate (human)

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • quinapril
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    quinapril
    1 interaction

    Monitor/Modify Tx

    immune globulin + quinapril

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • raloxifene
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    raloxifene
    1 interaction

    Monitor/Modify Tx

    immune globulin + raloxifene

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • ramipril
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ramipril
    1 interaction

    Monitor/Modify Tx

    immune globulin + ramipril

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • ramucirumab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ramucirumab
    1 interaction

    Monitor/Modify Tx

    immune globulin + ramucirumab

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • ranibizumab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ranibizumab
    1 interaction

    Monitor/Modify Tx

    immune globulin + ranibizumab

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

  • ravulizumab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ravulizumab
    1 interaction

    Monitor/Modify Tx

    immune globulin + ravulizumab

    admin. supplemental 600 mg ravulizumab dose w/in 4h of immune globulin cycle completion: combo may decr. ravulizumab levels, efficacy (FcRn blockade)

  • Rho(D) immune globulin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    Rho(D) immune globulin
    1 interaction

    Monitor/Modify Tx

    immune globulin + Rho(D) immune globulin

    monitor renal fxn, thrombosis s/sx; use lowest effective dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • ritlecitinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ritlecitinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + ritlecitinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • rituximab
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    rituximab
    1 interaction

    Monitor/Modify Tx

    immune globulin + rituximab

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • romiplostim
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    romiplostim
    1 interaction

    Monitor/Modify Tx

    immune globulin + romiplostim

    monitor platelets, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • ropeginterferon alfa-2b
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ropeginterferon alfa-2b
    1 interaction

    Monitor/Modify Tx

    immune globulin + ropeginterferon alfa-2b

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • ruxolitinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ruxolitinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + ruxolitinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • ruxolitinib topical
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ruxolitinib topical
    1 interaction

    Monitor/Modify Tx

    immune globulin + ruxolitinib topical

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • salsalate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    salsalate
    1 interaction

    Monitor/Modify Tx

    immune globulin + salsalate

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • segesterone (contraceptive)
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    segesterone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    immune globulin + segesterone (contraceptive)

    monitor thrombosis s/sx, especially w/ concomitant estrogen use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • sipuleucel-T
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    sipuleucel-T
    1 interaction

    Monitor/Modify Tx

    immune globulin + sipuleucel-T

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • sirolimus
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    immune globulin + sirolimus

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • sitagliptin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    sitagliptin
    1 interaction

    Monitor/Modify Tx

    immune globulin + sitagliptin

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • sodium tetradecyl sulfate
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    sodium tetradecyl sulfate
    1 interaction

    Monitor/Modify Tx

    immune globulin + sodium tetradecyl sulfate

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • sotatercept
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    sotatercept
    1 interaction

    Monitor/Modify Tx

    immune globulin + sotatercept

    monitor Hgb, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • sparsentan
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    sparsentan
    1 interaction

    Monitor/Modify Tx

    immune globulin + sparsentan

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • spironolactone
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    immune globulin + spironolactone

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • sulfate bowel prep
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    sulfate bowel prep
    1 interaction

    Monitor/Modify Tx

    immune globulin + sulfate bowel prep

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • sulindac
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    sulindac
    1 interaction

    Monitor/Modify Tx

    immune globulin + sulindac

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective sulindac dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • sunitinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + sunitinib

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • tacrolimus
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tacrolimus
    1 interaction

    Monitor/Modify Tx

    immune globulin + tacrolimus

    monitor tacrolimus levels, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. tacrolimus levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • tamoxifen
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tamoxifen
    1 interaction

    Monitor/Modify Tx

    immune globulin + tamoxifen

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • telavancin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    telavancin
    1 interaction

    Monitor/Modify Tx

    immune globulin + telavancin

    monitor ECG, renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. telavancin levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (additive effects)

  • telmisartan
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    telmisartan
    1 interaction

    Monitor/Modify Tx

    immune globulin + telmisartan

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • temsirolimus
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    temsirolimus
    1 interaction

    Monitor/Modify Tx

    immune globulin + temsirolimus

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • tenofovir alafenamide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tenofovir alafenamide
    1 interaction

    Monitor/Modify Tx

    immune globulin + tenofovir alafenamide

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • testosterone
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    testosterone
    1 interaction

    Monitor/Modify Tx

    immune globulin + testosterone

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • thalidomide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    thalidomide
    1 interaction

    Monitor/Modify Tx

    immune globulin + thalidomide

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • tiopronin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tiopronin
    1 interaction

    Monitor/Modify Tx

    immune globulin + tiopronin

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • tivozanib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    immune globulin + tivozanib

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • tofacitinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tofacitinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + tofacitinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • tolmetin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tolmetin
    1 interaction

    Monitor/Modify Tx

    immune globulin + tolmetin

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible; use lowest effective tolmetin dose, shortest effective tx duration: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • toremifene
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    toremifene
    1 interaction

    Monitor/Modify Tx

    immune globulin + toremifene

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • trametinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    trametinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + trametinib

    monitor thrombosis s/sx, especially in combo w/ dabrafenib; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • trandolapril
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    trandolapril
    1 interaction

    Monitor/Modify Tx

    immune globulin + trandolapril

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • tretinoin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    tretinoin
    1 interaction

    Monitor/Modify Tx

    immune globulin + tretinoin

    monitor thrombosis s/sx, especially during 1st month of tretinoin use; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • triamterene
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    immune globulin + triamterene

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • upadacitinib
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    upadacitinib
    1 interaction

    Monitor/Modify Tx

    immune globulin + upadacitinib

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • vadadustat
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    vadadustat
    1 interaction

    Monitor/Modify Tx

    immune globulin + vadadustat

    monitor Hgb, thrombosis s/sx; use lowest effective vadadustat dose, immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • valacyclovir
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    valacyclovir
    1 interaction

    Monitor/Modify Tx

    immune globulin + valacyclovir

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. acyclovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • valoctocogene roxaparvovec
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    valoctocogene roxaparvovec
    1 interaction

    Monitor/Modify Tx

    immune globulin + valoctocogene roxaparvovec

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • valsartan
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    valsartan
    1 interaction

    Monitor/Modify Tx

    immune globulin + valsartan

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • vamorolone
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    vamorolone
    1 interaction

    Monitor/Modify Tx

    immune globulin + vamorolone

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • vancomycin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    vancomycin
    1 interaction

    Monitor/Modify Tx

    immune globulin + vancomycin

    use lowest immune globulin dose, concentration and infusion rate possible; VANCOMYCIN IV: monitor renal fxn, vancomycin levels, ototoxicity; VANCOMYCIN PO: consider monitoring renal fxn, vancomycin levels, ototoxicity in pts w/ severe renal impairment, severe intestinal inflammation, or prolonged course >2 g/day: combo may incr. vancomycin levels, risk of nephrotoxicity, auditory, vestibular, other adverse effects (additive effects; incr. oral vancomycin absorption if inflamed or compromised gut mucosa)

  • varicella vaccine, live
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    varicella vaccine, live
    1 interaction

    Monitor/Modify Tx

    immune globulin + varicella vaccine, live

    vaccinate at least 2wk before or 8-11mo after IVIG tx; if vaccine given shortly before IVIG, consider re-vaccination: combo may result in inadequate vaccine response (antagonistic effects)

  • varicella zoster immune globulin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    varicella zoster immune globulin
    1 interaction

    Monitor/Modify Tx

    immune globulin + varicella zoster immune globulin

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • voclosporin
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    voclosporin
    1 interaction

    Monitor/Modify Tx

    immune globulin + voclosporin

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • von Willebrand factor
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    von Willebrand factor
    1 interaction

    Monitor/Modify Tx

    immune globulin + von Willebrand factor

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • vorinostat
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    vorinostat
    1 interaction

    Monitor/Modify Tx

    immune globulin + vorinostat

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

  • willow bark
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    willow bark
    1 interaction

    Monitor/Modify Tx

    immune globulin + willow bark

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible, especially w/ high-dose willow bark: combo may incr. risk of nephrotoxicity (additive effects, willow bark may contain salicylates)

  • ziv-aflibercept
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    ziv-aflibercept
    1 interaction

    Monitor/Modify Tx

    immune globulin + ziv-aflibercept

    monitor renal fxn, thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity, thromboembolism (additive effects)

  • zoledronic acid
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    zoledronic acid
    1 interaction

    Monitor/Modify Tx

    immune globulin + zoledronic acid

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. zoledronic acid levels, risk of nephrotoxicity, other adverse effects (additive effects)

  • zonisamide
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    zonisamide
    1 interaction

    Monitor/Modify Tx

    immune globulin + zonisamide

    monitor renal fxn; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects)

  • zopapogene imadenovec
  • Qivigy (immune globulin human-kthm) (immune globulin (human))
    +
    zopapogene imadenovec
    1 interaction

    Monitor/Modify Tx

    immune globulin + zopapogene imadenovec

    monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@7dc38998
  • hypersensitivity reaction, severe
  • anaphylaxis
  • Stevens-Johnson syndrome
  • erythema multiforme
  • nephrotoxicity
  • hyperproteinemia
  • hyponatremia
  • pseudohyponatremia
  • hyperviscosity
  • thromboembolism
  • aseptic meningitis
  • hemolytic anemia
  • transfusion-related acute lung injury
  • viral transmission risk

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@2c293fa3
  • headache
  • cough
  • infusion reaction
  • nausea
  • vomiting
  • rash
  • urticaria
  • fever
  • rigors
  • flushing
  • back pain
  • fatigue
  • asthenia
  • chest tightness
  • muscle cramps
  • blood pressure lability
  • URI
  • BUN or Cr elevated

Safety/Monitoring .

Monitoring Parameters
BUN/Cr at baseline, then periodically; urine output if acute renal failure risk; vital signs during infusion; blood viscosity at baseline, signs/symptoms of thrombosis if hyperviscosity risk; consider Hgb or Hct at baseline, then within 36-96h post-infusion if hemolysis risk

Pregnancy/Lactation .

Pregnancy

Clinical Summary

may use during pregnancy; no known risk of fetal harm based on human data

Lactation

Clinical Summary

may use while breastfeeding; no known risk of infant harm based on human data; no human data available to assess effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@56403c6c

Metabolism: for immune globulin: other; CYP450: unknown

Excretion: for immune globulin: other; Half-life: 20-72 days; Info: half-life varies among patients

Subclass: Immunoglobulins ; Myasthenia Gravis ; Neuropathy/Neuralgia

Mechanism of Action
for immune globulin: exact mechanism of action unknown; reestablishes normal immunoregulatory pathways

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Kedrion Biopharma Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@4c0b972

DEA/FDA: Rx

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information